Anti-MAG Neuropathy Plasma

Anti-MAG Neuropathy Plasma for Autoimmune Peripheral Nerve Research

Anti-MAG Neuropathy Plasma is collected from IRB-consented donors clinically diagnosed with anti-myelin-associated glycoprotein (anti-MAG) neuropathy and processed within one day of collection to preserve immunoglobulins, complement components, cytokines, and metabolites. Anti-MAG neuropathy is a genuinely autoantibody-mediated disorder, and plasma is the matrix in which its defining pathogenic antibody and downstream effector mechanisms are measured.

Anti-MAG Neuropathy Immunology and Why Plasma

• The disease is defined by a monoclonal IgM antibody, usually of kappa light chain type, directed against myelin-associated glycoprotein – a glycoprotein of peripheral nerve myelin that shares the HNK-1 carbohydrate epitope with related glycoconjugates.
• The IgM paraprotein almost always arises from an underlying IgM monoclonal gammopathy of undetermined significance, and less commonly from Waldenstrom macroglobulinaemia or another IgM-secreting lymphoproliferative disorder.
• Anti-MAG IgM deposits on the outer myelin lamellae and fixes complement, producing the widely spaced myelin lamellae seen on nerve biopsy ultrastructure and driving demyelination.
• The clinical phenotype is a slowly progressive, distal, sensory-predominant demyelinating polyneuropathy with prominent sensory ataxia and tremor – often described as distal acquired demyelinating symmetric (DADS) neuropathy – and distinguishing it from CIDP has direct therapeutic consequences.
• High anti-MAG IgM titre supports the diagnosis and is the primary serological readout; treatment strategies target the antibody-producing B-cell clone, most commonly with anti-CD20 therapy such as rituximab.
• Plasma is acellular and is the correct matrix for anti-MAG antibody titre, IgM paraprotein quantification, immunofixation, complement measurement, and neurofilament light chain. Cell-based B-cell work requires the paired PBMC product.

Donor Stratification Available

• Anti-MAG IgM antibody titre where serological testing is documented
• Underlying haematological context: IgM MGUS versus Waldenstrom macroglobulinaemia or other IgM lymphoproliferative disorder
• Paraprotein isotype and light chain type where characterised
• Clinical phenotype: sensory-predominant versus sensorimotor involvement, and presence of tremor or sensory ataxia
• Treatment exposure: rituximab-naive versus anti-CD20 treated, or prior IVIg or plasma exchange
• Disease duration and functional disability score where available
• Matched healthy controls available

Product Features

• Research Use Only (RUO)
• Plasma collected from clinically confirmed anti-MAG neuropathy donors
• Processed within one day of collection
• Choice of anticoagulant on request
• IRB-approved protocols and informed consent
• Custom aliquot volumes available upon request

De-identified Donor Data

• Verified anti-MAG neuropathy diagnosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies, and comorbidities
• Anti-MAG serology, paraprotein characterisation, and treatment history where documented
• Additional anti-MAG neuropathy-specific metadata available on request

Applications

• Anti-MAG antibody assay development, titre standardisation, and platform bridging
• IgM paraprotein quantification, immunofixation, and free light chain analysis
• Epitope mapping against MAG and HNK-1-bearing glycoconjugates
• Complement activation product measurement as a downstream effector readout
• Neurofilament light chain and other axonal damage marker measurement
• Cytokine, chemokine, and B-cell survival factor profiling, including BAFF and APRIL
• Pharmacodynamic monitoring of anti-CD20 and other B-cell-directed therapies
• Differential biomarker discovery to separate anti-MAG neuropathy from CIDP and other demyelinating neuropathies

Other Anti-MAG Neuropathy Specimen Types

• Anti-MAG Neuropathy Serum
• Anti-MAG Neuropathy Whole Blood
• Anti-MAG Neuropathy PBMC

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Anti-MAG neuropathy plasma is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To compare donor availability across conditions, visit our human plasma page.